Actively Recruiting
Evaluating Perioperative Inflammatory and Metabolic Biomarkers to Predict Complications in Colorectal and Gastric Cancer Surgery
Led by Bucharest Emergency Hospital · Updated on 2026-10-19
320
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether monitoring inflammatory and metabolic biomarkers around the time of surgery can help detect postoperative complications early in adults undergoing colorectal or gastric cancer surgery. This randomized controlled trial is conducted at Bucharest Emergency Clinical Hospital in Romania and aims to improve postoperative care by integrating biomarker assessments into recovery protocols. Participants are randomly assigned to one of two groups. The intervention group receives Enhanced Recovery After Surgery ERAS care combined with serial monitoring of biomarkers including blood lactate, procalcitonin, and glucose before and after surgery. Procalcitonin levels are measured at about 12 hours post-surgery and on days 3, 5, and 7. The control group receives standard perioperative care without additional biomarker monitoring. Both groups are followed for 30 days after surgery. During the study, participants will be assessed for postoperative complications such as infections and anastomotic leakage, hospital length of stay, readmissions, and mortality. Biomarker results will be combined with clinical findings to explore their usefulness in predicting complications. The study includes laboratory tests, clinical assessments, and follow-up visits within 30 days post-surgery to evaluate outcomes and patient recovery.
CONDITIONS
Brief Title
Perioperative Biomarkers in Colorectal and Gastric Cancer Surgery
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here